High frequency of chronic end-stage liver disease and hepatocellular carcinoma in a Hispanic population

被引:17
|
作者
Perez, A [1 ]
Anzaldua, M [1 ]
McCormick, J [1 ]
Fisher-Hoch, S [1 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Brownsville, TX 78520 USA
关键词
disparities; hepatitis; minority; prevalence;
D O I
10.1111/j.1440-1746.2003.03277.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Texas has the highest mortality from hepatocellular carcinoma in the USA. Because end-stage liver disease mortality is most marked in the Hispanic population in the Lower Rio Grande Valley, the aim of the present paper was to estimate the prevalence of end-stage liver disease and associated factors in Brownsville. Methods: A cross-sectional study was carried out, abstracting medical charts in a community-based clinic and a hospital. A matched case-control analysis was performed. Cases had an International Classification of Disease (9th revision; ICD9) code 155.0 or 571.0-9 (primary liver cancer or chronic liver disease) recorded; age- and sex-matched controls did not have these codes. A total of 176 cases and 352 controls was collected. The main outcome measure was the prevalence and risk factors for end-stage liver disease. Results: Conservative prevalence of end-stage liver disease: 126/100 000 (386/100 000, male). Eleven out of 176 had hepatocellular carcinoma. Median age was 57 years; 72% male, 94% Hispanic. Among significant risk factors were history of hepatitis (odds ratio (OR): 19.3; 95% confidence interval (CI): 8.0-46.4), any history of alcohol use (OR: 6.6; 95%CI: 4-10.8) and history of illegal drug use (OR: 1.9; 95%CI: 1.2-2.9). Fifteen cases with no known risk factors were classified as cryptogenic cirrhosis. Only four cases out of 176 had been referred for liver transplant. Conclusions: The prevalence of end-stage liver disease in the Lower Rio Grande Valley is extremely high, with no single satisfactory explanation and with acute health disparities. Careful follow up of cryptogenic cirrhosis in this population may or may not lead to a new source of liver disease. (C) 2004 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:289 / 295
页数:7
相关论文
共 50 条
  • [1] Liver Transplantation for Hepatocellular Carcinoma in the Model for End-Stage Liver Disease Era
    Levi, David M.
    Tzakis, Andreas G.
    Martin, Paul
    Nishida, Seigo
    Island, Eddie
    Moon, Jang
    Selvaggi, Gennaro
    Tekin, Akin
    Madrazo, Beatrice L.
    Narayanan, Govindarajan
    Garcia, Monica T.
    Feun, Lynn G.
    Tryphonopoulos, Panagiotis
    Skartsis, Nikolaos
    Livingstone, Alan S.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (05) : 727 - 734
  • [2] Stem cell therapy for hepatocellular carcinoma and end-stage liver disease
    Abdellateif, Mona S.
    Zekri, Abdel-Rahman N.
    [J]. JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2023, 35 (01)
  • [3] Stem cell therapy for hepatocellular carcinoma and end-stage liver disease
    Mona S. Abdellateif
    Abdel-Rahman N. Zekri
    [J]. Journal of the Egyptian National Cancer Institute, 35
  • [4] Liver Transplantation for Hepatocellular Carcinoma in the Model for End-Stage Liver Disease Era Discussion
    Hemming, Alan W.
    Johnson, Lynt
    O'Leary, Pat
    Perry, Roger
    Stain, Steven C.
    Levi, David M.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2010, 210 (05) : 735 - 736
  • [5] Model for end-stage liver disease score predicts survival in patients with hepatocellular carcinoma
    Contreras, C. M.
    Behrens, J.
    Cho, C. S.
    Mahvi, D. M.
    Rikkers, L. F.
    Weber, S. M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (02) : 96 - 96
  • [6] MELDEQ: An Alternative Model for End-Stage Liver Disease Score for Patients With Hepatocellular Carcinoma
    Marvin, Michael R.
    Ferguson, Nicole
    Cannon, Robert M.
    Jones, Christopher M.
    Brock, Guy N.
    [J]. LIVER TRANSPLANTATION, 2015, 21 (05) : 612 - 622
  • [7] Palliative Care for End-Stage Liver Disease Population
    Verma, Manisha
    Navarro, Victor
    [J]. JOURNAL OF PALLIATIVE MEDICINE, 2017, 20 (01) : 4 - 4
  • [8] Increased risk of hepatocellular carcinoma in viral hepatitis associated end-stage liver disease (ESLD).
    Perez, RG
    Zein, NN
    Steers, JL
    Wiesner, RH
    [J]. HEPATOLOGY, 1997, 26 (04) : 109 - 109
  • [9] Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease
    Antoury, Clara
    Lopez, Rocio
    Zein, Nizar
    Stoller, James K.
    Alkhouri, Naim
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2015, 7 (10) : 1427 - 1432
  • [10] Role of the model for end-stage liver disease and serum α-fetoprotein as prognostic predictors for hepatocellular carcinoma
    Huo, Teh-Ia
    Lee, Shou-Dong
    [J]. LIVER INTERNATIONAL, 2006, 26 (10) : 1300 - 1301